Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current HIV/AIDS Reports
Published in: Current HIV/AIDS Reports 5/2021

01-10-2021 | Human Immunodeficiency Virus | Complications of HIV and Antiretroviral Therapy (GA McComsey, Section Editor)

Cardiometabolic Complications in Youth With Perinatally Acquired HIV in the Era of Antiretroviral Therapy

Authors: Sahera Dirajlal-Fargo, Grace A. McComsey

Published in: Current HIV/AIDS Reports | Issue 5/2021

Login to get access

Abstract

Purpose of Review

Antiretroviral therapy (ART) scale-up has dramatically reduced rates of pediatric HIV mortality and morbidity. Children living with perinatally acquired HIV (PHIV) are now expected to live through adolescence and well into adulthood, such that adolescents now represent the largest growing population living with HIV. This review aims to discuss the prevalence and mechanisms for cardiometabolic comorbidities in the setting of newer ART regimens and the research gaps that remain.

Recent Findings

Data highlight the continued risks of subclinical cardiometabolic complications in PHIV in the setting of newer ART. Novel techniques in imaging and omics may help identify early cardiometabolic abnormalities in this young population and potentially identify early changes in the mechanistic pathways related to these changes.

Summary

Further studies to determine risk and management strategies of the cardiometabolic effects in PHIV adolescents, beyond ART, are warranted. Focus should be on prevention of these complications in youth to avoid new epidemic of diabetes and cardiovascular disease when these youths become aging adults.
Literature
1.
Organization TWH. Fact sheet HIV/AIDS. 2019.
2.
3.
Centers for Disease Control and Prevention. HIV Surveillance Report. 2017.
4.
Flynn PM, Abrams EJ. Growing up with perinatal HIV. AIDS (London, England). 2019;33(4):597–603.CrossRef
5.
Paula AA, Schechter M, Tuboi SH, Faulhaber JC, Luz PM, Veloso VG, et al. Continuous increase of cardiovascular diseases, diabetes, and non-HIV related cancers as causes of death in HIV-infected individuals in Brazil: an analysis of nationwide data. PloS one. 2014;9(4):e94636.
6.
Elbirt D, Mahlab-Guri K, Bezalel-Rosenberg S, Gill H, Attali M, Asher I. HIV-associated neurocognitive disorders (HAND). Israel Med Assoc J: IMAJ. 2015;17(1):54–9.
7.
Brady MT, Oleske JM, Williams PL, Elgie C, Mofenson LM, Dankner WM, et al. Declines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART era. Journal of acquired immune deficiency syndromes (1999). 2010;53(1):86–94.
8.
Patel K, Van Dyke RB, Mittleman MA, Colan SD, Oleske JM, Seage GR 3rd. The impact of HAART on cardiomyopathy among children and adolescents perinatally infected with HIV-1. AIDS (London, England). 2012;26(16):2027–37.CrossRef
9.
Savvoulidis P, Butler J, Kalogeropoulos A. Cardiomyopathy and heart failure in patients with HIV infection. Can J Cardiol. 2019;35(3):299–309.PubMedCrossRef
10.
Butler J, Greene SJ, Shah SH, Shah SJ, Anstrom KJ, Kim RJ, et al. Diastolic dysfunction in patients with human immunodeficiency virus receiving antiretroviral therapy: results from the CHART study. J Cardiac Fail. 2020;26(5):371–80.CrossRef
11.
• Lipshultz SE, Wilkinson JD, Thompson B, Cheng I, Briston DA, Shearer WT, et al. Cardiac effects of highly active antiretroviral therapy in perinatally HIV-infected children: The CHAART-2 Study. J Am Coll Cardiol. 2017;70(18):2240–7. This study compared echocardiograms from ART-exposed children to those of ART-unexposed children. Cardiac structure and function improved in PHIV children on ART compared to children in pre-ART area but did decline over time.
12.
Wilkinson JD, Williams PL, Yu W, Colan SD, Mendez A, Zachariah JPV, et al. Cardiac and inflammatory biomarkers in perinatally HIV-infected and HIV-exposed uninfected children. AIDS (London, England). 2018;32(10):1267–77.CrossRef
13.
Namuyonga J, Lubega S, Musiime V, Lwabi P, Lubega I. Cardiac dysfunction among Ugandan HIV-infected children on antiretroviral therapy. Pediatr Infect Dis J. 2016;35(3):e85–8.PubMedPubMedCentralCrossRef
14.
Majonga ED, Rehman AM, Simms V, McHugh G, Mujuru HA, Nathoo K, et al. High prevalence of echocardiographic abnormalities in older HIV-infected children taking antiretroviral therapy. AIDS (London, England). 2018;32(18):2739–48.CrossRef
15.
• Majonga ED, Rehman AM, McHugh G, Mujuru HA, Nathoo K, Odland JO, et al. Incidence and progression of echocardiographic abnormalities in older children with human immunodeficiency virus and adolescents taking antiretroviral therapy: a prospective cohort study. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2020;70(7):1372–8. Prospective longitudinal cohort in Zimbabwe of children on ART with echocardiograms at baseline and 18 months after; PHIV on ART have a high incidence of cardiac abnormalities that persist and progress over time.CrossRef
16.
• McCrary AW, Nyandiko WM, Ellis AM, Chakraborty H, Muehlbauer MJ, Koech MM, et al. Early cardiac dysfunction in children and young adults with perinatally acquired HIV. AIDS (London, England). 2020;34(4):539–48. In a large cohort in Kenya (n=643) with a mean age of 14 years old, echocardiogram was performed to assess for early cardiac dysfunction as measured by left ventricular strain and myocardial performance index. A total of 28% of children had early cardiac dysfunction. AZT exposure was independently association with strain.CrossRef
17.
Andrew McCrary WN, Michasel J Muehlbauer, Ibrahim Daug, Nathan M Thielman, Maggie Nguyen, Svati J. Shah, Gerald S. Bloomfield, editor Serum biomarkers identify cardiac dysfunction in youth living with HIV. CROI; 2021; Virtual.
18.
Terai M, Ohishi M, Ito N, Takagi T, Tatara Y, Kaibe M, et al. Comparison of arterial functional evaluations as a predictor of cardiovascular events in hypertensive patients: the Non-Invasive Atherosclerotic Evaluation in Hypertension (NOAH) study. Hypertension research: official journal of the Japanese Society of Hypertension. 2008;31(6):1135–45.CrossRef
19.
Mattace-Raso FU, van der Cammen TJ, Hofman A, van Popele NM, Bos ML, Schalekamp MA, et al. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. Circulation. 2006;113(5):657–63.PubMedCrossRef
20.
Shokawa T, Imazu M, Yamamoto H, Toyofuku M, Tasaki N, Okimoto T, et al. Pulse wave velocity predicts cardiovascular mortality: findings from the Hawaii-Los Angeles-Hiroshima study. Circ J. 2005;69(3):259–64.PubMedCrossRef
21.
McComsey GA, O’Riordan M, Hazen SL, El-Bejjani D, Bhatt S, Brennan ML, et al. Increased carotid intima media thickness and cardiac biomarkers in HIV infected children. AIDS (London, England). 2007;21(8):921–7.CrossRef
22.
Charakida M, Donald AE, Green H, Storry C, Clapson M, Caslake M, et al. Early structural and functional changes of the vasculature in HIV-infected children: impact of disease and antiretroviral therapy. Circulation. 2005;112(1):103–9.PubMedCrossRef
23.
Sainz T, Alvarez-Fuente M, Navarro ML, Diaz L, Rojo P, Blazquez D, et al. Subclinical atherosclerosis and markers of immune activation in HIV-infected children and adolescents: the CaroVIH study. Journal of acquired immune deficiency syndromes (1999). 2014;65(1):42–9.
24.
Bonnet D, Aggoun Y, Szezepanski I, Bellal N, Blanche S. Arterial stiffness and endothelial dysfunction in HIV-infected children. AIDS (London, England). 2004;18(7):1037–41.CrossRef
25.
Chanthong P, Lapphra K, Saihongthong S, Sricharoenchai S, Wittawatmongkol O, Phongsamart W, et al. Echocardiography and carotid intima-media thickness among asymptomatic HIV-infected adolescents in Thailand. AIDS (London, England). 2014;28(14):2071–9.CrossRef
26.
Marsico F, Lo Vecchio A, Paolillo S, DʼAndrea C, De Lucia V, Bruzzese E, et al. Left ventricular function, epicardial adipose tissue, and carotid intima-media thickness in children and adolescents with vertical HIV infection. Journal of acquired immune deficiency syndromes (1999). 2019;82(5):462–7.
27.
Charakida M, Loukogeorgakis SP, Okorie MI, Masi S, Halcox JP, Deanfield JE, et al. Increased arterial stiffness in HIV-infected children: risk factors and antiretroviral therapy. Antivir Ther. 2009;14(8):1075–9.PubMedCrossRef
28.
Eckard AR, Raggi P, Ruff JH, O’Riordan MA, Rosebush JC, Labbato D, et al. Arterial stiffness in HIV-infected youth and associations with HIV-related variables. Virulence. 2017;8(7):1265–73.PubMedPubMedCentralCrossRef
29.
Gleason RL Jr, Caulk AW, Seifu D, Rosebush JC, Shapiro AM, Schwartz MH, et al. Efavirenz and ritonavir-boosted lopinavir use exhibited elevated markers of atherosclerosis across age groups in people living with HIV in Ethiopia. J Biomech. 2016;49(13):2584–92.PubMedCrossRef
30.
•• Hanna DB, Guo M, Buzkova P, Miller TL, Post WS, Stein JH, et al. HIV infection and carotid artery intima-media thickness: pooled analyses across 5 cohorts of the NHLBI HIV-CVD collaborative. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2016;63(2):249–56. Through a NHLBI research consortium, this study analyzed IMT measurements from 5 studies and >2000 HIV+ individuals, including 221 6–29-year-old HIV+ and 58 HIV-. There was higher IMT in this group when compared to uninfected participants and the increase in IMT in HIV+ was strengthened when limited to PHIV.CrossRef
31.
• Dirajlal-Fargo S, Albar Z, Bowman E, Labbato D, Sattar A, Karungi C, et al. Subclinical vascular disease in children with human immunodeficiency virus in Uganda is associated with intestinal barrier dysfunction. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2020;71(12):3025–32. In a cross-sectional study, Ugandan PHIV, virally suppressed on ART, had evidence of higher IMT compared to HIV- which was independently associated with alteration in gut barrier.CrossRef
32.
Majonga ED, Chiesa ST, McHugh G, Mujuru H, Nathoo K, Odland JO, et al. Carotid intima media thickness in older children and adolescents with HIV taking antiretroviral therapy. Medicine. 2020;99(17):e19554.
33.
Abd-Elmoniem KZ, Unsal AB, Eshera S, Matta JR, Muldoon N, McAreavey D, et al. Increased coronary vessel wall thickness in HIV-infected young adults. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2014;59(12):1779–86.CrossRef
34.
Poredos P. Endothelial dysfunction in the pathogenesis of atherosclerosis. International angiology: a journal of the International Union of Angiology. 2002;21(2):109–16.
35.
Widlansky ME, Gokce N, Keaney JF Jr, Vita JA. The clinical implications of endothelial dysfunction. J Am Coll Cardiol. 2003;42(7):1149–60.PubMedCrossRef
36.
Gokce N, Keaney JF Jr, Hunter LM, Watkins MT, Nedeljkovic ZS, Menzoian JO, et al. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol. 2003;41(10):1769–75.PubMedCrossRef
37.
Hijmering ML, Stroes ES, Pasterkamp G, Sierevogel M, Banga JD, Rabelink TJ. Variability of flow mediated dilation: consequences for clinical application. Atherosclerosis. 2001;157(2):369–73.PubMedCrossRef
38.
Mahtab S, Zar HJ, Ntusi NAB, Joubert S, Asafu-Agyei NAA, Luff NJ, et al. Endothelial dysfunction in South African youth living with perinatally acquired human immunodeficiency virus on antiretroviral therapy. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2020;71(10):e672–9.CrossRef
39.
Dirajlal-Fargo S, Sattar A, Kulkarni M, Bowman E, Funderburg N, McComsey GA. HIV-positive youth who are perinatally infected have impaired endothelial function. AIDS (London, England). 2017;31(14):1917–24.CrossRef
40.
Bush KNV, Teel JL, Watts JA, Gore RS, Alvarado G, Harper NL, et al. Association of endothelial dysfunction and antiretroviral therapy in early HIV infection. JAMA Network Open. 2019;2(10):e1913615-e.
41.
Domingo P, Estrada V, López-Aldeguer J, Villaroya F, Martínez E. Fat redistribution syndromes associated with HIV-1 infection and combination antiretroviral therapy. AIDS Rev. 2012;14(2):112–23.PubMed
42.
Mallon PW, Miller J, Cooper DA, Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS (London, England). 2003;17(7):971–9.CrossRef
43.
Cames C, Pascal L, Ba A, Mbodj H, Ouattara B, Diallo NF, et al. Low prevalence of lipodystrophy in HIV-infected Senegalese children on long-term antiretroviral treatment: the ANRS 12279 MAGGSEN Pediatric Cohort Study. BMC Infect Dis. 2018;18(1):374.PubMedPubMedCentralCrossRef
44.
Bwakura-Dangarembizi M, Musiime V, Szubert AJ, Prendergast AJ, Gomo ZA, Thomason MJ, et al. Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapy. Pediatr Infect Dis J. 2015;34(2):e23-31.PubMedPubMedCentralCrossRef
45.
Crum-Cianflone N, Roediger MP, Eberly L, Headd M, Marconi V, Ganesan A, et al. Increasing rates of obesity among HIV-infected persons during the HIV epidemic. PloS one. 2010;5(4):e10106.
46.
Crum-Cianflone N, Tejidor R, Medina S, Barahona I, Ganesan A. Obesity among patients with HIV: the latest epidemic. AIDS Patient Care STDS. 2008;22(12):925–30.PubMedPubMedCentralCrossRef
47.
Koethe JR, Lagathu C, Lake JE, Domingo P, Calmy A, Falutz J, et al. HIV and antiretroviral therapy-related fat alterations. Nat Rev Dis Primers. 2020;6(1):48.PubMedCrossRef
48.
Jacobson DL, Lindsey JC, Coull BA, Mulligan K, Bhagwat P, Aldrovandi GM. The association of fat and lean tissue with whole body and spine bone mineral density is modified by HIV status and sex in children and youth. Pediatr Infect Dis J. 2018;37(1):71–7.PubMedPubMedCentralCrossRef
49.
Jacobson DL, Patel K, Siberry GK, Van Dyke RB, DiMeglio LA, Geffner ME, et al. Body fat distribution in perinatally HIV-infected and HIV-exposed but uninfected children in the era of highly active antiretroviral therapy: outcomes from the Pediatric HIV/AIDS Cohort Study. Am J Clin Nutr. 2011;94(6):1485–95.PubMedPubMedCentralCrossRef
50.
•• Sharma TS, Somarriba G, Arheart KL, Neri D, Mathew MS, Graham PL, et al. Longitudinal changes in body composition by dual-energy radiograph absorptiometry among perinatally HIV-infected and HIV-uninfected youth: Increased Risk of Adiposity Among HIV-infected Female Youth. Pediatr Infect Dis J. 2018;37(10):1002–7. PHIV on ART and HIV- controls were prospectively enrolled and DXA scans were obtained in a longitudinal fashion over a median of 2.5 years; PHIV females had significant increases in total percent body and trunk fat compared to HIV- females and PHIV males.PubMedPubMedCentralCrossRef
51.
Aurpibul L, Namwongprom S, Sudjaritruk T, Ounjaijean S. Metabolic syndrome, biochemical markers, and body composition in youth living with perinatal HIV infection on antiretroviral treatment. PloS one. 2020;15(3):e0230707.
52.
• Cohen S, Innes S, Geelen SP, Wells JC, Smit C, Wolfs TF, et al. Long-term changes of subcutaneous fat mass in HIV-infected children on antiretroviral therapy: a retrospective analysis of longitudinal data from two pediatric HIV-cohorts. PloS one. 2015;10(7):e0120927. A total of 218 PHIV children in South Africa and the Netherlands underwent DXA scans over a period of 3.5 years. Findings highlight ongoing subcutaneous fat loss in PHIV on ART associated with prior stavudine exposure.
53.
Arpadi SM, Bethel J, Horlick M, Sarr M, Bamji M, Abrams EJ, et al. Longitudinal changes in regional fat content in HIV-infected children and adolescents. AIDS (London, England). 2009;23(12):1501–9.CrossRef
54.
55.
Bourgi K, Rebeiro PF, Turner M, Castilho JL, Hulgan T, Raffanti SP, et al. Greater weight gain in treatment naive persons starting dolutegravir-based antiretroviral therapy. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2019;70(7):1267–74.CrossRef
56.
Sax PE, Erlandson KM, Lake JE, McComsey GA, Orkin C, Esser S, et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials [published online ahead of print, 2019 Oct 14]. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2019;ciz999.
57.
Venter WDF, Moorhouse M, Sokhela S, Fairlie L, Mashabane N, Masenya M, et al. Dolutegravir plus two different prodrugs of tenofovir to treat HIV. N Engl J Med. 2019;381(9):803–15.PubMedCrossRef
58.
Lamorde M, Atwiine M, Owarwo NC, Ddungu A, Laker EO, Mubiru F, et al. Dolutegravir-associated hyperglycaemia in patients with HIV [published online ahead of print, 2020 Feb 24]. Lancet HIV. 2020;S2352–3018(20)30042–4.
59.
Sahera Dirajlal-fargo WLAK, Matthew E. Levy, Anne K. Monroe, Amanda D. Castel, Natella Rakhmanina, editor Effect of integrase inhibitors on weight gain in children and adolescents with HIV. CROI; 2020 03/2020; Virtual.
60.
Giacomet V, Lazzarin S, Manzo A, Paradiso L, Maruca K, Barera G, et al. Body fat distribution and metabolic changes in a cohort of adolescents living with HIV switched to an antiretroviral regimen containing dolutegravir. Pediatr Infect Dis J. 2021;40(5):457–9.PubMedCrossRef
61.
• Turkova A, editor Dolutegravir-based ART is superior to NNRI/PI-based ART in children and adolescents. CROI; 2021; virtual. Findings from ODYSSEY trial, an open-label multicountry randomized trial presented at CROI 2021. PHIV randomized to DTG highlighted a slight but significant increase in BMI compared to standard of care.
62.
63.
Alexopoulos N, Katritsis D, Raggi P. Visceral adipose tissue as a source of inflammation and promoter of atherosclerosis. Atherosclerosis. 2014;233(1):104–12.PubMedCrossRef
64.
El Kamari V, Moser C, Hileman CO, Currier JS, Brown TT, Johnston L, et al. Lower pretreatment gut integrity is independently associated with fat gain on antiretroviral therapy. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2019;68(8):1394–401.CrossRef
65.
Gojanovich GS, Jacobson DL, Jao J, Russell JS, Van Dyke RB, Libutti DE, et al. Mitochondrial dysfunction and insulin resistance in pubertal youth living with perinatally acquired HIV. AIDS Res Hum Retroviruses. 2020;36(9):703–11.PubMedPubMedCentralCrossRef
66.
Hulgan T, Ramsey BS, Koethe JR, Samuels DC, Gerschenson M, Libutti DE, et al. Relationships between adipose mitochondrial function, serum adiponectin, and insulin resistance in persons with HIV after 96 weeks of antiretroviral therapy. Journal of acquired immune deficiency syndromes (1999). 2019;80(3):358–66.
67.
Jao J, Jacobson DL, Russell JS, Wang J, Yu W, Gojanovich GS, et al. Perinatally acquired HIV infection is associated with abnormal blood mitochondrial function during childhood/adolescence. AIDS (London, England). 2021;Publish Ahead of Print.
68.
McComsey GA, Daar ES, O’Riordan M, Collier AC, Kosmiski L, Santana JL, et al. Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202. J Infect Dis. 2013;207(4):604–11.PubMedCrossRef
69.
Bouter KE, van Raalte DH, Groen AK, Nieuwdorp M. Role of the gut microbiome in the pathogenesis of obesity and obesity-related metabolic dysfunction. Gastroenterology. 2017;152(7):1671–8.PubMedCrossRef
70.
Koay WLA, Lindsey JC, Uprety P, Bwakura-Dangarembizi M, Weinberg A, Levin MJ, et al. Intestinal integrity biomarkers in early antiretroviral-treated perinatally HIV-1-infected infants. J Infect Dis. 2018;218(7):1085–9.PubMedPubMedCentralCrossRef
71.
•• Dirajlal-Fargo S, El-Kamari V, Weiner L, Shan L, Sattar A, Kulkarni M, et al. Altered intestinal permeability and fungal translocation in Ugandan children with HIV. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2019. In this cross-sectional study performed in Uganda, PHIV had evidence of alteration in intestinal permeability compared to HIV- and HEU children despite viral suppression on ART. In PHIV, these markers correlated with systemic inflammation.
72.
Sahera Dirajlal-Fargo DJ, Wendy Yu, Ayesha Mirza, Mitchell E. Geffner, Jennifer Jao, Grace A. McComsey , on behalf of the Pediatric HIV/AIDS Cohort Study (PHACS). Gut markers’ associations with body fat in youth living with perinatally-acquired HIV. Conference of Retroviruses and Opportunistic Infections-2021; Virtual2021.
73.
Blázquez D, Ramos-Amador JT, Saínz T, Mellado MJ, García-Ascaso M, De José MI, et al. Lipid and glucose alterations in perinatally-acquired HIV-infected adolescents and young adults. BMC Infect Dis. 2015;15:119.PubMedPubMedCentralCrossRef
74.
Espiau M, Yeste D, Noguera-Julian A, González-Tomé MI, Falcón-Neyra L, Gavilán C, et al. Metabolic syndrome in children and adolescents living with HIV. Pediatr Infect Dis J. 2016;35(6):e171–6.PubMedCrossRef
75.
Espiau M, Yeste D, Noguera-Julian A, Soler-Palacín P, Fortuny C, Ferrer R, et al. Adiponectin, leptin and inflammatory markers in HIV-associated metabolic syndrome in children and adolescents. Pediatr Infect Dis J. 2017;36(2):e31–7.PubMedCrossRef
76.
Frigati LJ, Jao J, Mahtab S, Asafu Agyei NA, Cotton MF, Myer L, et al. Insulin resistance in South African youth living with perinatally acquired HIV receiving antiretroviral therapy. AIDS Res Hum Retroviruses. 2019;35(1):56–62.PubMedPubMedCentralCrossRef
77.
Geffner ME, Patel K, Jacobson DL, Wu J, Miller TL, Hazra R, et al. Changes in insulin sensitivity over time and associated factors in HIV-infected adolescents. AIDS (London, England). 2018;32(5):613–22.CrossRef
78.
Innes S, Abdullah KL, Haubrich R, Cotton MF, Browne SH. High prevalence of dyslipidemia and insulin resistance in HIV-infected prepubertal African children on antiretroviral therapy. Pediatr Infect Dis J. 2016;35(1):e1-7.PubMedPubMedCentralCrossRef
79.
Paganella MP, Cohen RA, Harris DR, de Souza Kuchenbecker R, Sperhacke RD, Kato SK, et al. Association of dyslipidemia and glucose abnormalities with antiretroviral treatment in a cohort of HIV-infected Latin American children. Journal of acquired immune deficiency syndromes (1999). 2017;74(1):e1-e8.
80.
Santiprabhob J, Chokephaibulkit K, Khantee P, Maleesatharn A, Phonrat B, Phongsamart W, et al. Adipocytokine dysregulation, abnormal glucose metabolism, and lipodystrophy in HIV-infected adolescents receiving protease inhibitors. Cytokine. 2020;136:155145.
81.
Santiprabhob J, Tanchaweng S, Maturapat S, Maleesatharn A, Lermankul W, Sricharoenchai S, et al. Metabolic disorders in HIV-infected adolescents receiving protease inhibitors. Biomed Res Int. 2017;2017:7481597.PubMedPubMedCentralCrossRef
82.
Takemoto JK, Miller TL, Wang J, Jacobson DL, Geffner ME, Van Dyke RB, et al. Insulin resistance in HIV-infected youth is associated with decreased mitochondrial respiration. AIDS (London, England). 2017;31(1):15–23.CrossRef
83.
Dirajlal-Fargo S, Musiime V, Cook A, Mirembe G, Kenny J, Jiang Y, et al. Insulin resistance and markers of inflammation in HIV-infected Ugandan children in the CHAPAS-3 trial. Pediatr Infect Dis J. 2017;36(8):761–7.PubMedPubMedCentralCrossRef
84.
Dirajlal-Fargo S, Shan L, Sattar A, Bowman E, Gabriel J, Kulkarni M, et al. Insulin resistance and intestinal integrity in children with and without HIV infection in Uganda. HIV Med. 2020;21(2):119–27.PubMedCrossRef
85.
Moran A, Jacobs DR Jr, Steinberger J, Steffen LM, Pankow JS, Hong CP, et al. Changes in insulin resistance and cardiovascular risk during adolescence: establishment of differential risk in males and females. Circulation. 2008;117(18):2361–8.PubMedCrossRef
86.
Hannon TS, Janosky J, Arslanian SA. Longitudinal study of physiologic insulin resistance and metabolic changes of puberty. Pediatr Res. 2006;60(6):759–63.PubMedCrossRef
87.
Dimock D, Thomas V, Cushing A, Purdy JB, Worrell C, Kopp JB, et al. Longitudinal assessment of metabolic abnormalities in adolescents and young adults with HIV-infection acquired perinatally or in early childhood. Metabolism: clinical and experimental. 2011;60(6):874–80.
88.
• Jao J, Yu W, Patel K, Miller TL, Karalius B, Geffner ME, et al. Improvement in lipids after switch to boosted atazanavir or darunavir in children/adolescents with perinatally acquired HIV on older protease inhibitors: results from the Pediatric HIV/AIDS Cohort Study. HIV Med. 2018;19(3):175–83. PHIV enrolled in PHACS who switched to ATV/r or DRV/r compared to those who remained on older PI had a more rappid reduction in lipids.PubMedCrossRef
89.
Rutstein RM, Samson P, Fenton T, Fletcher CV, Kiser JJ, Mofenson LM, et al. Long-term safety and efficacy of atazanavir-based therapy in HIV-infected infants, children and adolescents: the Pediatric AIDS Clinical Trials Group Protocol 1020A. Pediatr Infect Dis J. 2015;34(2):162–7.PubMedPubMedCentralCrossRef
90.
Munger AM, Chow DC, Playford MP, Parikh NI, Gangcuangco LM, Nakamoto BK, et al. Characterization of lipid composition and high-density lipoprotein function in HIV-infected individuals on stable antiretroviral regimens. AIDS Res Hum Retroviruses. 2015;31(2):221–8.PubMedPubMedCentralCrossRef
91.
Wong G, Trevillyan JM, Fatou B, Cinel M, Weir JM, Hoy JF, et al. Plasma lipidomic profiling of treated HIV-positive individuals and the implications for cardiovascular risk prediction. PloS one. 2014;9(4):e94810.
92.
• Dirajlal-Fargo S, Sattar A, Yu J, Albar Z, Chaves FC, Riedl K, et al. Lipidome association with vascular disease and inflammation in HIV+ Ugandan children. AIDS (London, England). 2021. In this small pilot study, Ugandan PHIV (n=20) compared to HIV- (n=20) had evidence of altered lipidomic panel and increased lipid species known to be inflammatory and associated with CVD.
93.
Bowman ER, Kulkarni M, Gabriel J, Cichon MJ, Riedl K, Belury MA, et al. Altered lipidome composition is related to markers of monocyte and immune activation in antiretroviral therapy treated human immunodeficiency virus (HIV) infection and in uninfected persons. Front Immunol. 2019;10:785.PubMedPubMedCentralCrossRef
94.
Puri P, Wiest MM, Cheung O, Mirshahi F, Sargeant C, Min HK, et al. The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology (Baltimore, MD). 2009;50(6):1827–38.CrossRef
95.
Taramasso L, Di Biagio A, Bovis F, Forlanini F, Albani E, Papaioannu R, et al. Switching to integrase inhibitors unlinked to weight increase in perinatally HIV-infected young adults and adolescents: a 10-year observational study. Microorganisms. 2020;8(6):864.PubMedCentralCrossRef
96.
al TNe, editor Optimization to dolutegravir-based ART in a cohort of virally suppressed adolescents is associated with an increase in the rate of BMI change and odds of becoming overweight. AIDS 2020; 2020; virtual.
97.
Yeoh DK, Campbell AJ, Bowen AC. Increase in body mass index in children with HIV, switched to tenofovir alafenamide fumarate or dolutegravir containing antiretroviral regimens. Pediatr Infect Dis J. 2021;40(5):e215–6.PubMedCrossRef
Metadata
Title
Cardiometabolic Complications in Youth With Perinatally Acquired HIV in the Era of Antiretroviral Therapy
Authors
Sahera Dirajlal-Fargo
Grace A. McComsey
Publication date
01-10-2021
Publisher
Springer US
Published in
Current HIV/AIDS Reports / Issue 5/2021
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-021-00574-x

Other articles of this Issue 5/2021

Current HIV/AIDS Reports 5/2021 Go to the issue

The Science of Prevention (R Heffron and K Ngure, Section Editors)

Lessons Learned from Longer Acting Reversible Contraception Applied to Longer Acting HIV Prevention Technologies

Complications of HIV and Antiretroviral Therapy (GA McComsey, Section Editor)

Cardiovascular Disease Risk Among Transgender People with HIV

Central Nervous System and Cognition (SS Spudich, Section Editor)

Advances in the Experimental Models of HIV-Associated Neurological Disorders

HIV Pathogenesis and Treatment (AL Landay and NS Utay, Section Editors)

Analytical Treatment Interruption in HIV Trials: Statistical and Study Design Considerations

Correction

Correction to: A Review of Interventions to Enhance HIV Medication Adherence

Behavioral-Bio-Medical Interface (RJ DiClemente and JL Brown, Section Editors)

A Review of Interventions to Enhance HIV Medication Adherence
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits